While no firm conclusions may be drawn from measurements on so few samples, the data suggest that the peaks in the tumour radioactivity may be related to a fairly general increase in the metabolic activity of the tumour and not to variations in the amount of a single substance.
This suggests that, in those tumours which exhibit rhythmic variations in radioactivity, metabolic activity may not proceed at a uniform rate but may occur in regular bursts of activity. If this hypothesis were true the rise and fall in radioactivity in thetumour could be explained by a number of phosphorus atoms being concerned in the synthesis or degradation of a single molecule of a compound. For example, the synthesis of one molecule of lecithin, containing 1 atom of phosphorus, requires the participation of 7 atoms of phosphorus in various forms, while the oxidation of one molecule of glucose results in th-formation of about 32 high energy phosphate bonds.
If many of the phosphate compounds required for the various metabolic reactions are derived from extracellular sources, the rise and fall in activity could be explained by an influx of radioactive phosphorus compounds into the cell at the start of a period of metabolic activity with a subsequent removal of surplus inorganic phosphate and other compounds. The consistent increase in acid-soluble radioactivity at the peaks supports this suggestion.
In view of the fact that many of the tumours which exhibit a periodicity in uptake of phosphorus 32 are hormone dependent, it is interesting to note that increases in lipid, acid-soluble and RNA phosphorus could be expected to occur following administration of cestrogens (Mueller 1957) and that increases in acid-soluble and RNA phosphorus 32 have been observed in a breast tumour following treatment with stilbcestrol.
These studies do not give any indication of the extent to which the rise and fall in radioactivity may be related to cell division. However, it seems unlikely that, even if the tumour contained a synchronous population of cells, cell division alone could account for increases in activity as large as those which have been observed.
Much further work remains to be done. More detailed studies are required of the distribution of phosphorus 32 within tumour cells and their components, as are studies of metabolic activity in tumours to attempt to determine whether specific reactions may occur, or be made to occur, in regular cycles rather than as continuous processes. Day et al. (1957) have shown that antibodies to rat fibrinogen, after labelling with 1311, will localize with considerable specificity in some transplantable rat tumours. Studies were also done in dogs bearing spontaneous tumours. Using 1311-labelled and purified antiserum to dog fibrinogen, it was found that the presence of the injected dose was in some dog tumours substantially higher than in blood or normal organs.
The mechanism of action is thought to be as follows: As the tumour grows, there is a deposition of fibrin in the tumour stroma either as the result of a reaction of the host against the developing tumour or as the result of blood vessel injury by the invading neoplasm. The antibody to fibrin is then deposited in the tumour either because it binds to the fibrin already deposited there, or because it is already bound to the circulating fibrinogen and is brought along as the fibrinogen is converted to fibrin.
Epsilon amino caproic acid (EACA), an antifibrinolytic agent, was found to decrease the rate of loss of the 1311-antibody from tumours in which the radioactive material is deposited.
For human studies, rabbits were immunized with human fibrinogen and the resultant antisera purified, labelled with 1311, tested for sterility and frozen until used. Forty-nine patients with advanced neoplastic disease were included in this study. All were skin tested with normal rabbit y-globulin before intravenous administration of the 1311-antibody to human fibrinogen. They were given iodide solution to decrease the thyroid uptake of catabolized 1311. Also 4-6 g EACA was administered every six hours. The patients were given 0-4-2 millicuries of labelled antibody intravenously and were examined with a scintillation scanner one and three days later.
Of the total of these 49 patients, and 44 others reported by Dewey et al. (1963) 
